Tecan expands its commercial reach, its capabilities and its US and Asia presence with the acquisition of Paramit Corporation
- Tecan to acquireParamit Corporation, a leading OEMdeveloper and manufacturer of medical devices and life sciences instruments,for a total consideration of USD 1.0billion (CHF 920 million)
- In full year 2021, Paramit is expected to generate aroundUSD280min sales (CHF 257m)and around USD 50m EBITDA (CHF 46m),before acquisition-related costs
- Transaction expected to be immediately and significantly accretive to earnings per share (EPS) upon closing
- Adds complementary expertise, broadens design, development and manufacturing capabilities
- Expansion into the attractive and fast-growing medical device market segment, close to Tecan’s own core competencies
- Combined entity with leading OEM offering, well diversified, differentiated and fully complementary portfolio of products and services
- Significantly strengthens geographic footprint in the US, the largest life sciences and healthcare market in the world
Männedorf, Switzerland, June 23 2021 – The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has entered into a definitive agreement to acquire US-based Paramit Corporation and its affiliates (“Paramit”) for a total purchase consideration of USD 1.0 billion (CHF 920 million). Paramit, headquartered in Morgan Hill (CA), US, is a leading OEM developer and manufacturer of medical devices and life sciences instruments. With the addition of approximately USD 300 million in revenues (CHF 276 million) expected in 2022, the acquisition will further extend Tecan’s position in solutions for life sciences and in-vitro diagnostics (IVD). It will also add a new business vertical in the attractive and fast-growing market for medical devices. The acquisition will bring significant engineering as well as cost-competitive manufacturing capabilities, both in North America and in the APAC region. Equipped with proprietary computer-directed assembly technology, these facilities deliver ultra-flexible production planning, while reducing the potential for errors (“zero-defect manufacturing”).
Tecan CEO, Dr. Achim von Leoprechting, commented: “We are delighted to bring the Paramit Team into the Tecan Group. The company’s extensive OEM offering and its state-of-the-art development and manufacturing facilities will strengthen our market reach and enable us to more effectively meet customer needs, scaling innovation from research all the way to the clinic. In addition to extending our core markets of life science research and diagnostics, the acquisition will also open a whole new growth market in the field of medical devices. At Tecan, we share Paramit’s strong customer-centric culture, expertise and track record in quality and regulatory affairs, which are key differentiators in the industry and essential for OEM success in regulated markets. Paramit’s geographic presence is complementary to that of Tecan, benefitting both parties. Tecan will gain new highly efficient manufacturing capacity in Asia and a strong presence for its OEM business in North America. At the same time, Paramit will gain access to Tecan’s existing sales channels in other parts of the world. These opportunities will help us to broaden our customer base and offering, while further strengthening our ability to serve the healthcare market.”
Paramit – unique combination of design engineering with a proprietary assembly concept
Established in 1990, Paramit is headquartered in Silicon Valley in the United States. It has facilities in Morgan Hill (CA) and in Penang, Malaysia. Paramit’s recently acquired R&D facility in Boston (MA) specializes in technology development and the design of complex products and systems for multiple sectors, complementing Tecan’s existing R&D capabilities. Across these different sites, the company employs over 1’000 associates. Since 2011, Paramit Corporation has been privately held by Altaris Capital Partners, LLC, a healthcare-dedicated investment firm based in New York (NY).
Paramit has developed and/or manufactured several FDA-approved medical devices, including surgical instruments, critical modules and systems for surgical robotics, point-of-care and personal testing devices, as well as diagnostic systems.
Paramit also works with life science companies developing and manufacturing high-precision instrumentation. Its clients are mainly US-based companies commercializing a range of products for genomics, proteomics and cell-analysis including flow cytometers, microfluidic instruments, and systems for electrophoresis, imaging, high-sensitivity biomarker detection, microarrays and sample preparation.
Paramit’s patented, computer-directed assembly technology, vPoke®, resolves complex mechanical assembly into tightly controlled assembly steps for medical device and life science instruments. The process generates a rich device history record, providing component traceability, while reducing the potential for errors (“zero-defect manufacturing”).
Billoo Rataul, President and CEO of Paramit said: “It has been an incredible journey establishing Paramit as a global leader in the life sciences and medical device industries alongside Altaris. We are incredibly proud of the organization we have built together and look forward to our future with Tecan. Combining Paramit’s leading design and manufacturing expertise with Tecan’s strengths is the next logical step for our growing business. Becoming part of the Tecan Group will take our industry-leading offering to new customers in expanding markets. It will enable us to further develop our expertise in life sciences and clinical diagnostics and address an extended range of scientific applications. Tecan’s commitment to our strategic position in medical devices will boost our growth in that sector. Our customers stand to gain from the combined supply chain depth and Tecan’s broad expertise in design and manufacturing of solutions for highly regulated environments. We passionately share Tecan’s customer-focused culture and its mission to contribute to the quality of life of humankind. We are therefore excited to begin this new chapter in the development of our organization.”
Strengthens Tecan’s OEM offering, expanding into attractive medical device market
The acquisition of Paramit will strengthen Tecan’s OEM offering in solutions for the life sciences and IVD markets. It will also significantly expand the total addressable market for Tecan’s Partnering Business. It will broaden access to the custom design and manufacturing segment and enable the business to expand into the fast-growing market of medical devices. Although this is a new business vertical for Tecan, it leverages the company’s existing core competencies. Paramit will bring state-of-the-art, high-quality, cost-competitive manufacturing services, together with a proven, highly scalable, proprietary approach to complex assembly (vPoke®) and an established track record in scaling innovation for partners in regulated markets. Paramit will also substantially expand Tecan’s production engineering and industrialization capabilities.
Paramit’s R&D presence in the technology hubs of Silicon Valley and Boston will help drive the expansion of the combined customer base and Tecan’s engineering capabilities in the US, the world’s largest market for the life sciences and healthcare.
Significantly enhances value proposition for combined customer base
The combined entity will have an industry-leading OEM offering, including extensive experience in quality and regulatory affairs, and a well-diversified, differentiated and fully complementary portfolio of products and services. The transaction will strengthen the combined entity’s design, development and manufacturing capabilities, and enable it to further improve its services. Thereby, it will provide a more comprehensive value proposition for customers in the healthcare industry.
While Tecan already has significant relationships with key players in fast-growing segments of the healthcare industry, Paramit brings with it a number of significant accounts and a strong presence in North America. Likewise, Paramit will be able to leverage Tecan’s existing OEM customer base and its commercial channel to further expand its reach in the European and Asian markets, including China, and beyond.
Compelling financial benefits
The acquisition will be immediately accretive to earnings per share (EPS) upon closing. With strong growth and healthy operating margins recorded over the past five years, Paramit is expected to generate around USD 280 million in sales (CHF 257 million) and approximately USD 50 million EBITDA (CHF 46 million) in the full year 2021 (before acquisition-related costs). This transformation of Tecan into a >CHF 1 billion revenue and >CHF 200 million EBITDA company will provide the Group with critical mass and scale, further enhancing its already strong operating cash flows. This strengthened financial profile will fuel future growth, both organic and through additional acquisitions.
Tecan anticipates substantial commercial and cost synergies to be achieved through a range of opportunities, including synergies in the supply chain and the internalization of supplies of certain parts, modules and sub-assemblies.
Financing of the transaction
Upon closing of the transaction, the total purchase consideration of USD 1.0 billion (CHF 920 million) will be funded through a mix of cash on hand (net liquidity of Tecan as of December 31, 2020: CHF 467.7 million), the issuance of new shares and a bond offering. Tecan has obtained committed bridge financing with respect to the purchase price from Credit Suisse.
Tecan’s debt leverage after the transaction is expected to be at around 1.0x net debt/EBITDA and is expected to decrease quickly, driven by cash generation of the combined entity.
For the equity portion of the financing, Tecan intends to issue new shares from existing authorized share capital corresponding to less than 10% of its share capital.
The transaction, which is expected to be completed in the coming months, is subject to the satisfaction of customary closing conditions. Upon completion, Paramit will be included in the consolidated financial statements of the Tecan Group as part of the Partnering Business segment.
Additional information on the Paramitwebpage:
- About Paramit: www.paramit.com/
- Customer portfolio (examples): www.paramit.com/portfolio/
- vPoke® assembly system: www.paramit.com/vpoke-mechanical-assembly/
Wilmer Cutler Pickering Hale and Dorr LLP is serving as Tecan’s legal advisor in the transaction and Bär & Karrer is acting as Tecan’s Swiss legal advisor relating to the financing.
Conference Call and Webcast
Tecan will host a conference call and webcast on June 24, 2021 at 14:00 CEST (8:00 a.m. Eastern Time) to provide more information on this announcement. The webcast and accompanying slides can be accessed on the company’s website www.tecan.com under Investor Relations.
The dial-in numbers for the conference call are as follows:
For participants from Europe: +41 (0)58 310 50 00 or +44 (0)207 107 0613 (UK)
For participants from the US: +1 (1) 631 570 5613
Participants should if possible dial in 15 minutes before the start of the event.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automation solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2020, Tecan generated sales of CHF 731 million (USD 778 million; EUR 683 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Beter Bed Holding announces the issue of 946,167 new ordinary shares23.7.2021 18:00:00 CEST | Press release
Beter Bed Holding N.V. (“BBH” ISIN NL0000339703), the Netherlands’ leading sleep specialist in retail, wholesale and B2B, announces the issue of 946,167 new ordinary shares of the Company against an issue price of € 6.82. The issue of shares is meant to remediate the impact on the Company’s solvency from the repayment of the perpetual loan, as announced in the interim results press release dated 21 July 2021. The net proceeds of the Offering will be used to strengthen our financial position and to provide the Company with the financial flexibility to accelerate the execution of its growth strategy 2025 as presented during the AGM of 12 May 2021. The increased attention for health and well-being, due to COVID-19, is expected to lead to increased demand for quality sleep as one of the three pillars of health. The investment program driven by our strategy is starting through the launch of a new shop format, subscription label Leazzzy, investments in data analytics and acceleration of onli
Arcadis reports transactions under its current share buyback program23.7.2021 12:00:00 CEST | Press release
Amsterdam, July 23, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 91.282 of its own shares in the period from 16 July up to and including 22 July 2021 at an average price of €34.59. The consideration of this repurchase was €3.2 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021. The total number of shares repurchased under this program to date is 1.7 million shares for a total consideration of €56.0 million. For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/ -End- Improving quality of life FOR FURTHER INFORMATION PLEASE CONTACT: ARCADIS INVESTOR RELATIONS Jurgen Pullens Mobile: +31 6 51599483 E-mail: email@example.com ABOUT ARCADIS Arcadis is the leading global desig
Vaisala Corporation Half Year Financial Report January–June 202123.7.2021 08:00:00 CEST | Press release
Vaisala Corporation Half Year Financial Report July 23, 2021 at 9.00 a.m. (EEST) Vaisala Corporation Half Year Financial Report January–June2021 Excellent growth continued in second quarter Secondquarter 2021 highlights Orders received EUR 120.1 (95.9) million, increase 25%Order book at the end of the period EUR 165.3 (145.3) million, increase 14%Net sales EUR 109.5 (91.4) million, increase 20%Operating result (EBIT) EUR 10.9 (7.9) million, 10.0 (8.7) % 0f net salesEarnings per share EUR 0.25 (0.16)Cash flow from operating activities EUR 11.1 (-1.1) million January–June 2021 highlights Orders received EUR 226.3 (185.6) million, increase 22%Net sales EUR 201.5 (178.6) million, increase 13%Operating result (EBIT) EUR 19.0 (13.1) million, 9.5 (7.3) % 0f net salesEarnings per share EUR 0.43 (0.27)Cash flow from operating activities EUR 29.4 (4.2) million Market development and businessoutlook for 2021 Market for high-end industrial instruments is expected to continue growth after strong re
FLOW TRADERS Q221 RESULTS23.7.2021 07:30:00 CEST | Press release
FLOW TRADERS Q221 RESULTS Amsterdam, the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q221 results and 2021 Half Year report. Highlights Market ETP Value Traded decreased 14% quarter-on-quarter and decreased 14% H121 vs H120Flow Traders ETP Value Traded decreased 15% quarter-on-quarter and decreased 6% H121 vs H120Flow Traders recorded NTI of €94.4m in Q221 reflecting a more normalised market environment. This compares to NTI of €142.2m in Q121 and €229.9m in Q220. H121 NTI was €236.6m vs €724.8m in H120Total operating expenses of €54.1m incurred in Q221 which includes €0.6m of one-off COVID-19 and business continuity plan-related expenses577 FTEs as at 30 June 2021 compared to 566 FTEs as at 31 March 2021Q221 EBITDA reached €40.3m with a margin of 43% contributing to H121 EBITDA of €119.6m with a margin of 51%Q221 Net Profit amounted to €28.7m with basic EPS of €0.66. H121 Net Profit amounted to €90.2m with basic EPS of €2.05IFR/IFD came into force on 26 Ju
Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million23.7.2021 07:00:00 CEST | Press release
Press Release July 23, 2021 Signify reports second quarter sales of EUR 1.6 billion, operational profitability of 10.9% and a free cash flow of EUR 104 million Second quarter 20211 Signify's installed base of connected light points increased from 83 million in Q1 21 to 862 million in Q2 21 Sales of EUR 1,609 million; 9.6% nominal sales growth and CSG of 14.1%LED-based sales represented 82% of total sales (Q2 2020: 80%)Adj. EBITA margin improved by 190 bps to 10.9%Net income increased to EUR 82 million (Q2 20: EUR 81 million)Free cash flow of EUR 104 million (Q2 20: EUR 158 million)Net debt/EBITDA ratio of 1.7x (Q2 20: 2.4x) Eindhoven, the Netherlands – Signify (Euronext: LIGHT), the world leader in lighting, today announced the company’s second quarter 2021 results. “In the second quarter we saw an acceleration of the pace of recovery in comparison to the first three months of the year. We successfully executed our strategy as demand for our connected lighting offers and our growth pla
Norsk Hydro: Andre kvartal 2021 – Rekordresultater og fortsatt positivt markedssentiment23.7.2021 07:00:00 CEST | Pressemelding
Norsk Hydro ASA rapporterte en justert EBITDA på 6.598 millioner kroner i andre kvartal 2021, en økning fra 2,794 millioner kroner i samme kvartal i fjor. Fortsatt oppgang i verdensøkonomien bidrar til økt etterspørsel etter aluminium og aluminiumprodukter. Forretningsområdene Hydro Aluminium Metal og Hydro Extrusions rapporterte rekordresultater for kvartalet. Rekordresultat i Aluminium Metal på grunnlag av økte priser og produktpremier på LMERobust drift, forbedringsprogrammet foran skjema Sterke prestasjoner i Extrusions og framdrift i vekstprosjekterStyrking av bærekraftposisjon med investeringer for vekst i resirkuleringSalget av forretningsområdet Hydro Rolling til KPS Capital Partners fullført Høyere all-in metallpriser og volumer i Aluminium Metal, bedre marginer og volumer i Extrusions og bedre resultater fra Hydro Energy bidro positivt til justert EBITDA. Disse positive elementene ble delvis utliknet av høyere råvarekostnader oppstrøms og negative valutaeffekter. Den globale
Norsk Hydro: Second quarter 2021 - Record results and continued positive market sentiment23.7.2021 07:00:00 CEST | Press release
Norsk Hydro ASA posted second-quarter 2021 adjusted EBITDA of NOK 6,598 million, up from NOK 2,794 million in the same quarter last year. Continued global economic recovery is supporting increased demand for aluminium and aluminium products. Hydro Aluminium Metal and Hydro Extrusions business areas reported record quarterly results. Record result in Aluminium Metal supported by LME prices and premiumsRobust operations, improvement program ahead of plan Strong performance in Extrusions and progress on growth initiativesStrengthening sustainability position with growth investments in recyclingSale of Hydro Rolling business area to KPS Capital Partners completed Higher all-in metal prices and volumes in Aluminium Metal, improved margins and volumes in Extrusions, and better results from Hydro Energy contributed positively to adjusted EBITDA. These positive elements were partly offset by higher raw material costs upstream and negative currency effects. The second quarter saw a continuation